Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients
about
Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalitiesRefining the approach to vaccines against influenza A viruses with pandemic potential.Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment.Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients.Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
P2860
Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Safety and immunogenicity of a ...... and immunocompromised patients
@ast
Safety and immunogenicity of a ...... and immunocompromised patients
@en
type
label
Safety and immunogenicity of a ...... and immunocompromised patients
@ast
Safety and immunogenicity of a ...... and immunocompromised patients
@en
prefLabel
Safety and immunogenicity of a ...... and immunocompromised patients
@ast
Safety and immunogenicity of a ...... and immunocompromised patients
@en
P2093
P2860
P356
P1476
Safety and immunogenicity of a ...... and immunocompromised patients
@en
P2093
Alexander Geisberger
Brian A Crowe
Christoph Stephan
Daniel Portsmouth
Eva Distler
Eva M Wagner
Gerald Aichinger
Hartmut J Ehrlich
Maikel V W van der Velden
P Noel Barrett
P2860
P304
P356
10.1128/CVI.00065-14
P577
2014-04-16T00:00:00Z